Antonarakis et al. showed that AR-V7 mRNA in circulating tumor cells (CTCs) might be enhanced by AR-directed therapies including abiraterone acetate and enzalutamide, and its expression was associated with poor prognosis [226]. The gene discussed is AR; the disease is neoplasm.